Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Finished

CarboMed Development of carbohydrate based anticancer agents

Coordinator
Stichting Radboud Universiteit, Netherlands
Runs
1 September 2022 to 29 February 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101082163

What the project is doing

In the project's own words, from its summary on CORDIS.

CarboMed will assess the commercial viability of targeting cancer cell glycosylation as a next-generation therapeutic strategy to treat cancer in the clinic. Carbohydrates (glycans) coat the cell of every organism. The glycosylation pattern of cancer cells is, however, very different from that of healthy cells and is associated with aggressive and invasive forms of cancers. By combining our knowledge on carbohydrate chemistry and cancer immunology we targeted the cancer-cell protecting carbohydrate coat, hampering the cancer's ability to grow and metastasize.

In this project, we aim to deliver a technical and commercial proof-of-concept for targeting the glycosylation of cancer cells to ultimately enable clinical studies

Topics

Who is involved

OrganisationCityCountryRole
Stichting Radboud UniversiteitNijmegenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI